INBS

INBS

USD

Intelligent Bio Solutions Inc. Common Stock

$1.290-0.020 (-1.527%)

リアルタイム価格

Healthcare
医療機器
米国

価格チャート

主要指標

市場指標
企業ファンダメンタルズ
取引統計

市場指標

始値

$1.310

高値

$1.310

安値

$1.270

出来高

0.00M

企業ファンダメンタルズ

時価総額

8.8M

業種

医療機器

United States

取引統計

平均出来高

0.21M

取引所

NCM

通貨

USD

52週レンジ

安値 $1現在値 $1.290高値 $3.04

関連ニュース

GlobeNewswire

Intelligent Bio Solutions Expands Middle East Market Reach with Arabic Integration in Drug Screening System

NEW YORK, March 31, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (NASDAQ:INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today

もっと見る
Intelligent Bio Solutions Expands Middle East Market Reach with Arabic Integration in Drug Screening System
GlobeNewswire

Intelligent Bio Solutions to Highlight Proprietary Drug Testing Technology at 2025 NDASA Conference and Trade Show

NEW YORK, March 28, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (NASDAQ:INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing

もっと見る
Intelligent Bio Solutions to Highlight Proprietary Drug Testing Technology at 2025 NDASA Conference and Trade Show
GlobeNewswire

Intelligent Bio Solutions Secures Key U.S. Patent, Strengthening IP Protection Ahead of Planned 2025 Market Entry

Company's 6th U.S. patent adds to comprehensive IP portfolio protecting its unique drug screening technology Patent protection strengthens Company's competitive position as it prepares for planned entry into

もっと見る
Intelligent Bio Solutions Secures Key U.S. Patent, Strengthening IP Protection Ahead of Planned 2025 Market Entry
GlobeNewswire

Intelligent Bio Solutions to Expand U.S. IP Portfolio with Expected Patent Grant

NEW YORK, March 20, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (NASDAQ:INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today

もっと見る
Intelligent Bio Solutions to Expand U.S. IP Portfolio with Expected Patent Grant